Provided Financing for Initial Scope of Activities for the All-Party Parliamentary Group for Longevity
Produced the First Ever Longevity Industry Landscape Overview Analytical Reports
Succeeded in Having the World Health Organization Add New Code for “Ageing Related” Diseases

The UK's Leading Non-profit Foundation Specifically Focused on Longevity and the Paradigm Shift from Treatment to Prevention
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biogerontology Research Foundation - Summary</td>
<td>3</td>
</tr>
<tr>
<td>Biogerontology Research Foundation Scope, History and Agenda 2019 - 2020</td>
<td>4</td>
</tr>
<tr>
<td>Biogerontology Research Foundation History and Scope of Activities</td>
<td>5</td>
</tr>
<tr>
<td>The BGRF is Supporting the Activities of the UK ALI-Party Parliamentary Group for Longevity</td>
<td>6</td>
</tr>
<tr>
<td>The BGRF is Supporting the Launch of an Artificial Intelligence Centre for Longevity at King’s College London</td>
<td>7</td>
</tr>
<tr>
<td>Paradigm Shift from Treatment to Prevention</td>
<td>8</td>
</tr>
<tr>
<td>The New Frontier - from Precision Medicine to Precision Health</td>
<td>9</td>
</tr>
<tr>
<td>The BGRF Established Extension Code for “Ageing Related” During the World-Health Organization’s ICD-11 Revisions</td>
<td>10</td>
</tr>
<tr>
<td>The Biogerontology Research Foundation Predicted the Rise of the Longevity Industry 3 Years in Advance</td>
<td>11</td>
</tr>
<tr>
<td>The Biogerontology Research Foundation Produced the First Ever Longevity Industry Landscape Overview Reports</td>
<td>12</td>
</tr>
<tr>
<td>Reports by the Biogerontology Research Foundation and Aging Analytics Agency: 2013 - 2015</td>
<td>13</td>
</tr>
<tr>
<td>UK Longevity Industry Landscape Overview Q4 2018</td>
<td>14</td>
</tr>
<tr>
<td>The Biogerontology Research Foundation is Supporting the Launch of Swiss Longevity Foundation in Geneva, Switzerland in 2019</td>
<td>15</td>
</tr>
<tr>
<td>Biogerontology Research Foundation Board of Trustees</td>
<td>16</td>
</tr>
<tr>
<td>Proposal for Cooperation and Collaboration</td>
<td>17</td>
</tr>
<tr>
<td>Contact Information</td>
<td>18</td>
</tr>
</tbody>
</table>
Biogerontology Research Foundation - Summary

I. Active Involvement in UK Longevity Policy, Politics and Governance Initiatives

The Biogerontology Research Foundation has always made progressive policy proposals relating to Longevity a core element of its activities, and has recently made the decision to significantly expand its scope of activities in this regard, interfacing with both national and international policy-related organizations to further the United Kingdom’s activities relating to Longevity politics and governance, including providing inputs to optimize the long-term strategy of the All-Party Parliamentary Group for Longevity’s Blueprint and Framework for a National UK Healthy Longevity Development Strategy.

II. Cross-Sector Dialogue with All Major UK Longevity Industry Players

A focus on cross-sector dialogue, projects and initiatives spanning government, industry, academia and other relevant spheres of activity, Longevity Swiss Foundation aims to achieve a maximum level of synergy and convergence, growing every aspect of United Kingdom’s Longevity ecosystem to scale.

III. Scientific Research to Further R&D on AI for Longevity and行动able Biomarkers of Ageing

The Biogerontology Research Foundation has an extremely strong history of applying AI for ageing research (including more than a dozen peer-reviewed scientific articles and projects on this topic) and on the development of practically-implementable and actionable panels of biomarkers of ageing (such as its MouseAge crowdfunding initiative, which enabled the development of ageing biomarkers based on deep-learning analysis of photographs), and actively prioritizes collaboration on these specific niches).


The Biogerontology Research Foundation is committed to working alongside progressive financial institutions including pension funds, insurance companies, private wealth banks and other relevant entities to roadmap initiatives and policy proposals to turn the problem of ageing population into the economic opportunity of Healthy Longevity.
The **Biogerontology Research Foundation** is the UK’s leading non-profit focused on Longevity and on expediting the coming paradigm shift from disease treatment to personalized precision prevention.

It was the main initial donor that provided financial and organisational support to Longevity International UK for the purpose of establishing the APPG for Longevity.

It was also actively involved in the successful initiative of adding a new extension code for “ageing-related diseases” accepted in 2018 by the World Health Organization during the last revisions of its International Classification of Diseases framework - the closest any group has come to classifying ageing as a disease.

It has been working since 2008 to develop the UK’s Longevity Industry and the field of Geroscience (The Science of Longevity) to a level of mainstream prominence and recognition since 2008 -- nearly a decade before the Longevity Industry rose to its current state of acceptance by the mainstream investors, the global scientific community, the public and the media landscape.

While the topic of Longevity is now accepted by even the most conservative industry, scientific and media professionals, it took tireless years of work to achieve, and the Biogerontology Research Foundation has been on the forefront of these developments.

**The Biogerontology Research Foundation Has Been Committed for to Developing the United Kingdom's Longevity Industry, Academic Sphere and its State of Longevity Policy, Politics and Governance for More than 10 Years.** Now that the UK Longevity Ecosystem has Reached a state of Unprecedented Mainstream Acceptance and Prominence, the Biogerontology Research Foundation is Expanding its Scope to Help Develop the Global Longevity Industry to Scale.
Biogerontology Research Foundation History and Scope of Activities

**Founded in 2008 by Prominent Longevity Scientists Including Alex Zhavoronkov**
Inspired by Dr. Aubrey de Grey and Founded in prominent Longevity Scientists including Alex Zhavoronkov, the BGRF was officially launched as a formal UK non-profit foundation in 2008.

**Landmark Production of Several Global Longevity Industry Landscape Overview Analytical Reports**
Throughout 2008 - 2013, the BGRF produced a number of key analytical reports on industries that eventually emerged into the present unified Longevity Industry, laying the groundwork for the analytical frameworks later used for its Longevity Industry Landscape Overviews, which were officially published in 2017. This marks the first time that any entity had ever published comprehensive industry overviews of the entire global Longevity industry.

**Successful Addition of New Extension Code for Age Related Diseases via World Health Organization**
In 2017 the Biogerontology Research Foundation submitted a proposal to classify ageing as a disease during the ICD-11 revisions. In 2018, the proposal was partially implemented in the form of a new extension code for age related diseases, the closest any organization has ever come globally to officially classifying ageing as a disease.

**Publication of Longevity Industry in UK Landscape Overview Q4 2018 (Second Edition) - 1100 Pages**
In 2018 the Biogerontology Research Foundation released a second extended edition of its previous Longevity Industry in UK Landscape Overview Report, 1100+ pages in length, which provided key inputs into the current Longevity Industry, Academic and Policy Landscape on the UK for the APPG for Longevity.

**Support of the Artificial Intelligence Centre for Longevity at King’s College London**
The Biogerontology Research Foundation supported the structuring of the strategic agenda for a new AI Centre for Longevity as part of the Ageing Research at King’s (ARK) alongside Aging Analytics Agency and Insilico Medicine, offering key inputs into how to most optimally leverage the UK’s strengths in AI R&D to help support cutting-edge AI for Longevity, Preventive Medicine and Precision Health R&D at King’s College in London.

**Provided Financing to Support Initial Scope of Activities for All-Party Parliamentary Group for Longevity**
In Q2 2019 the Biogerontology Research Foundation was the primary source of financing for the support and execution of the All-Party Parliamentary Group for Longevity initial scope of activities, and also offered key strategic inputs on the APPG for Longevity’s agenda for 2019-2020 alongside Aging Analytics Agency.
Supporting the All-Party Parliamentary Group for Longevity
The BGRF will continue to support the activities of the All-Party Parliamentary Group for Longevity by offering key inputs relevant for its long-term strategy as one of its Supporting Partners.

Support of AI Centres for Precision Health and LifeTime Wellness (Financial, Social, Psychological Wellness)
The Biogerontology Research Foundation is utilizing its wealth of knowledge on the ways that AI can be used to accelerate R&D in Preventive Medicine, Precision Health and Longevity to support the launch of AI Centres for Longevity and AI Centres for LifeTime Wellness, to make the UK a global leader in AI for Longevity Research.

Support and Launch of the Longevity Swiss Foundation
The BGRF is utilizing its expertise in pushing forward progressive policy proposals with UK politics and governance organizations within the UK to help guide the launch of similar activities in Switzerland through the Longevity Swiss Foundation, a Geneva-based non-profit aiming to make Switzerland a leading international Longevity hub.

Ongoing Development of Distributed Longevity Knowledge Platform Longevity.International
The Biogerontology Research Foundation will continue its efforts on the ongoing development and optimization of its distributed knowledge platform Longevity.International for Longevity industry networking and overall cross-sector and inter-stakeholder industry optimization.

Creating Database of Relevant Partners for Contribution to the UK National Longevity Development Strategy
The Biogerontology Research Foundation will participate in the construction of a comprehensive database of institutional partners relevant for the formulation and execution of the UK National Longevity Development Strategy being created by the All-Party Parliamentary Group for Longevity, in order to identify the most prospective organizations that can assist in the design and ultimate execution of the APPG’s goals to increase national HALE.

Creating Database of Scientifically-Viable but Stalled/ Paused UK Longevity & Preventive Medicine R&D Projects
As part of its ongoing support of the All-Party Parliamentary Group for Longevity, the Biogerontology Research Foundation will participate in the construction of a comprehensive database of all projects either funded via the UK Government, or commercial projects, relating to Longevity and Preventive Medicine which failed to achieve market-readiness of their technologies and other deliverables not due to failures in science or technology, but due to a lack of follow-up funding, in order to support cost-effective R&D to help the APPG for Longevity meet its goals.
The Biogerontology Research Foundation has been on the forefront of advocating for and facilitating the paradigm shift from treatment to prevention since its inception, pushing the Longevity Industry away from ineffective reactionary single-disease treatments towards personalized, preventive and precision care. The foundation is pleased to see a large number of developments in this area over the past several years, and to see the paradigm of preventive medicine being embraced by progressive healthcare systems across the globe.
The Biogerontology Research Foundation has also been active in the shift from Precision Medicine to Precision Health through its many activities in the spheres of AI for ageing research and the development of practical, actionable biomarkers of ageing, urging the UK to focus on the intensive application of AI to preventive medicine and personalized care, utilizing the latest innovations in AI, Longevity, Biomarkers of Ageing and Advanced Biomedicine to become nation leading the world in the optimization of national health and an extension of national Healthy Longevity (Health-Adjusted Life Expectancy).
The BGRF is Supporting the Activities of the UK All-Party Parliamentary Group for Longevity

The Biogerontology Research Foundation was instrumental in the initial groundwork and establishment of the UK All-Party Parliamentary Group for Longevity. It provided the initial financing that enabled implementation of its first scope of activities.

Additionally, its Managing Trustee, Dmitry Kaminskiy, currently serves as Head of International Cooperation for the APPG for Longevity Secretariat, Longevity International UK.

It is currently working alongside its strategic partner Aging Analytics Agency to provide the APPG for Longevity key inputs on the UK Longevity industry, academic and policy landscapes in order to support the APPG’s development of a Blueprint and Framework for a Government-led National Longevity Development Strategy. Part of its activities in this sphere have included supplying the APPG for Longevity Officers, Members and Advisory Board Members with key insights and conclusions from its Longevity Industry in UK Landscape Overview Q4 2018 analytical report, as well as offering feedback on the first draft of the APPG’s agenda for 2019 - 2020.
The BGRF Provided the Financing to Support the Initial Scope of Activities of the UK All-Party Parliamentary Group on Longevity

All Party Parliamentary Group for Longevity

Preventive Medicine
Innovations in Healthcare
Problem of Ageing Population
Financial Reform for Pension System

Supporting Partners

Executive Team Longevity International UK APPG for Longevity
Biogerontology Research Foundation was also critical in the initial stages of planning and development of the soon to be launched Artificial Intelligence Centre for Longevity and King’s College London, which will serve as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics. The main concept of precision medicine is providing health care which is individually tailored on the basis of a person’s genes, lifestyle and environment. Developments in AI and the growing availability of health data, presents an opportunity to make precise personalized patient care a clinical reality. King’s College is an ideal location for the first AI Centre for Longevity in the UK because it has dedicated divisions and resources both for AI and for Longevity. Furthermore, being located in London, it is in an ideal physical location to engage in cross-sector and industry-academic collaboration.

The Biogerontology Foundation has over the course of its more than 10 years of activity always placed a great emphasis on the role that AI can play in accelerating the development of the Longevity Industry. Now, the Biogerontology Research Foundation is utilizing its long-standing expertise in this area to support the first AI Centre for Longevity at King’s College.
Corporate Partners

Development of Biomarkers of Ageing

AI Centre for Longevity

AI Centre for Financial Wellness

AI Medical Centres

Swiss Ministry of Health

Corporate Partners

Doctors and Clinics

Third-Party Ecosystem Participants

UK AI Centre Trifecta

Building UK AI Longevity Ecosystem
The BGRF Established Extension Code for “Ageing Related” During the World-Health Organization’s ICD-11 Revisions

In 2017 the Biogerontology Research Foundation submitted a joint-proposal with the International Longevity Alliance to the 11th round of revision for the World Health Organization’s International Classification of Diseases system (the main disease classification system used by the majority of developed nations) to classify ageing as a disease based on existing clinical evidence of the causal mechanisms underlying aging and the effectiveness of various interventions in modulating those causal mechanisms. In 2018, the World Health Organization approved the addition of a new extension code for “ageing related” that can be added to any existing disease code. This is the closest any team on the globe has come to classifying ageing as a disease, and gives major financial incentives for drug companies to develop medicines capable of treating the mechanisms of ageing directly.

“The ICD is not just a taxonomy. It greatly influences how drugs are prescribed in most nations, because a physician’s justification for writing a prescription must typically be documented in terms of an ICD code describing the diagnosis. As such, the addition of an extension code to denote aging may have a really huge impact on the financial rewards that drug developers can expect to reap if they bring treatments for age-related ill-health to the market.” - Aubrey de Grey, CSO of SENS Research Foundation
The BGRF Established Extension Code for “Ageing Related” During the World-Health Organization’s ICD-11 Revisions

The proposal involved collecting and summarizing available clinical data supporting the existence of various presumed causal mechanisms of ageing, clinical data demonstrating the fact that such mechanisms can be modulated by environmental and genetic factors, as well as clinical data demonstrating the efficacy of known therapeutic interventions capable of modifying these mechanisms, in order to argue that the process of biological ageing fits the disease classification criteria used by the WHO. In 2018, the WHO partially accepted the proposal through the addition for a new extension code for “Ageing-related”, designated through the extension code XT9T under the existing category “Temporality”, which can be appended to any other relevant condition included in ICD-11. It can also be used in the formation of newly recognized conditions, such as “Ageing-related primary immunodeficiency”, “Ageing-related lung atrophy”, etc. Some of these conditions are already incorporated into ICD-11, while others can be created in the future as permanent codes, as needed. The International Classification of Diseases is essential for the registration of new drugs and therapies, and the absence of aging and the lack of aging-related conditions in the previous round of ICD revision (ICD-10) was a major barrier for the development of lifespan and healthspan-extending interventions. ICD-10 had a code called “Senility”, now replaced by “Old age” in ICD-11, but it was not concrete enough to be used. This can create new opportunities for the development and registration of innovative anti-aging biomedical technologies.
The Biogerontology Research Foundation Predicted the Rise of the Longevity Industry 3 Years in Advance

The Biogerontology Research Foundation was the first entity to produce comprehensive Longevity Industry Landscape Overviews in coordination with its strategic partner, Aging Analytics Agency. While the majority of its industry analytical resources have since been taken over by Aging Analytics Agency, the BGRF was pivotal to the initial development of those analytical frameworks.

Now in its 11th year of operations, the Biogerontology Research Foundation has been on the frontlines of developing the Longevity Industry to scale since its very inception.

Dmitry Kaminskiy, Managing Trustee of the Biogerontology Research Foundation, boldly predicted in 2014 that the Longevity Industry would see an inflection point in its development in 2017, becoming a recognized industry in the eyes of conservative investors, business analysts and top business media. This was at a time when investors and geroscientists alike were highly skeptical of the industry’s emergence within the next decade.

This prediction turned out to be true. 2017 witnessed an unprecedented rise in the number of Longevity-focused companies and investment deals, the emergence of half a dozen of geroscience-focused VC firms, coupled with widespread coverage of Longevity as a topic by mainstream media including The Economist, Financial Times and Bloomberg.

The BGRF Produced the First Ever Longevity Industry Landscape Overview Reports

The Biogerontology Research Foundation not only forecast the true dawn of the Longevity Industry years before its mainstream recognition, but was willing to put its reputation at stake with a bold yet precise prediction when no one else saw it coming. Their confidence stems from their reliance on tangible and quantitative predictive metrics, including the use of cross-disciplinary and synergetic analytical tools and frameworks to map the enormous diversity and complexity of the Longevity Industry.

Today, the fruits of their labor significantly contributed to the exponential growth of Longevity as a topic in the mainstream, including its acceptance by business experts, media and even governments. The UK, for example, has listed Aging Population as one of its four grand challenges and launched a government-backed Healthy Aging Industrial Strategy Challenge Fund. Other governments have also launched similar strategic national development plans devoted to Longevity. Leading media brands, including TIME, Forbes, Bloomberg and others regularly publish Longevity-oriented cover stories. High-profile conferences on the subject of Longevity are more numerous than ever before.

The Biogerontology Research foundation has been involved in charting the rise of the Longevity sphere since its inception and remained at the forefront throughout the past half decade. Thus, they are uniquely positioned to produce both broadly-accessible reports and specialized case studies for specialized clientele including companies, investment firms, family offices and government agencies.
Reports by the Biogerontology Research Foundation and Aging Analytics Agency

2013 - 2015

SPECIALIZED LONGEVITY INDUSTRY REPORTS

2013

Analytical Regenerative Medicine Industry Framework

2014

Investing in Regenerative Medicine: Technology Analysis and Market Outlook

2015

Commercializing Aging Research Series

BIG DATA IN AGING AND AGE - RELATED DISEASES
In July 2018, the Biogerontology Research Foundation in coordination with Aging Analytics Agency released the industry analytical report, *Longevity Industry in the UK Landscape Overview 2018*. 845 pages in length, the report outlined the history, present state and future of the Longevity industry in the UK. This regional case study documented the factors that make the UK well-suited as a global Longevity industry hub, and provided insight on how to foster that potential. To reach its conclusion, the report profiled hundreds of relevant companies and investors, provided an overview of major UK Longevity nonprofits and research labs, and identified major industry trends. The report then utilised comprehensive infographics to distill industry data and conclusions into easily understandable summaries, and offered guidance on how various stakeholders and government officials could work to strengthen the industry and assist the UK to reach its full potential as a global Longevity industry hub.

The astonishing growth in the UK Longevity sector witnessed in the months following that report prompted the Biogerontology Research Foundation and Aging Analytics Agency to perform a rapid reassessment just six months following the release of the first edition of the report. The updated version documents new developments, profiles novel players, and adds a revamped executive summary. The number of companies and investors highlighted in the Second Edition have almost doubled compared to the original, featuring in-depth profiles of 260 companies and 250 investors in the UK Longevity sphere. The 1100-page report also provided key inputs into the initial formulation of the All-Party Parliamentary Group for Longevity's long-term strategy and agenda for 2019-2020.
In 2019, to compliment its analytical reports, Aging Analytics Agency released an advanced online Longevity Analytics Platform and database featuring interactive visuals which can transform static analytical reports into dynamic infographics updated in real-time. This platform will enable complex interactions between industry entities and stakeholders to be visualized, filtered, searched and thus more easily understood.

This IT-platform is being continuously updated with real-time industry developments and upgraded with the integration of novel analytics elements including:

- A stakeholder smart-matching engine
- Supply chain analysis
- Customized report production
- Peer-to-peer, distributed stakeholder ranking systems
- Big data analytics and other advanced tools and techniques

As part of its partnership with Aging Analytics Agency, the Biogerontology Research Foundation is supporting the development of this integrated system of online interactive Longevity Industry IT-platforms.

Longevity.International: A Distributed Knowledge and Networking Platform

The Biogerontology Research Foundation is supporting the ongoing development of a decentralized Longevity knowledge and networking platform, Longevity.International.

The platform is open to qualified stakeholders, and will serve as the framework for industry optimization and cross-disciplinary dialogue and collaboration between companies, investors, entrepreneurs, scientists and government officials. The overarching aim of the platform is to promote the synergistic and integrated development of the Longevity Industry to maximize the benefits of all industry stakeholders.

The Longevity Industry continues to grow in size but remains highly fragmented, with different stakeholders displaying disparate opinions on where it is headed and how long it will take to get there. Their platform aims to deliver a framework for proper industry unification.

The platform aims to serve as a kind of Wikipedia and Encyclopedia Britannica for the global Longevity Industry, and will feature significant crossovers of functionality with Aging Analytics Agency’s online Longevity Analytics IT-platforms.
Longevity Swiss Foundation is a leading Geneva-based Longevity Policy Non-profit and Think Tank working to leverage the national strengths and potentials of Switzerland in order to turn the nation into a world-leading Longevity Hub through the coordinated development of Longevity Politics and Governance, the Longevity BioTech Industry, Preventive Medicine, Precision Health and the emerging Longevity Financial Industry. Leveraging Switzerland’s existing reputation as a hub for independent international policy organizations like the World Economic Forum, the United Nations, UNESCO, the World Health Organization and Others, Swiss Longevity Foundation aims to turn Switzerland into the leading international hub for cross-sector and cross-nation Longevity Development projects and initiatives.

Longevity Swiss Foundation will work with the participation of proactive corporate and institutional partners to interface with relevant Swiss governmental ministries, departments, agencies and members of Swiss Parliament to establish a National Swiss Longevity Development Framework, as well as the establishment of a parliamentary body equivalent to the United Kingdom’s All Party Parliamentary Group on Longevity. The Biogerontology Research Foundation is a founding partner of Longevity Swiss Foundation, and will be utilizing its experience in pushing the UK Longevity Policy landscape forward in order to help the foundation make similar progress on the front of Longevity Policy, Politics and Governance within the Swiss political ecosystem.
Jim Plante
TRUSTEE
Jim Plante is an investor and technology leader. His work has helped the companies reach dominant positions in their industries regarding both value and offering best-of-breed offerings.

Dmitry Kaminskiy
MANAGING TRUSTEE
Dmitry Kaminskiy is the Founder of Aging Analytics Agency, Managing Partner of Deep Knowledge Ventures, and a prominent Longevity Investor and Thought-Leader.

João Pedro de Magalhães
TRUSTEE
João Pedro de Magalhães is a Portuguese microbiologist. His lab at the University of Liverpool studies aging through both computational and experimental approaches. His ultimate goal is to cure human aging.

Richard Faragher
TRUSTEE
Richard Faragher is Professor of Biological Gerontology at the University of Brighton and past Chair of the British Society for Research on Ageing, the International Association of Biomedical Gerontology and the American Aging Association.

Jim Mellon
TRUSTEE
Jim Mellon, the British billionaire ex-fund manager who became a convert to the emerging science of anti-ageing a few years ago, and has decided to pour his money into his own biotech ventures.
I. Cooperation with Governmental, International and Non-Governmental Organizations

The Biogerontology Research Foundation is interested in cooperation, collaboration and initiating dialogue from a number of relevant organizations actively involved in UK governance, ranging from government ministries, agencies and departments, to relevant policy-focused NGOs and think-tanks, and other relevant organizations in order to facilitate the optimized development of the nation's Longevity politics and governance sphere.

II. Cooperation and Sponsorship with Biomedical, Public Policy and Financial Organizations

The Biogerontology Research Foundation is interested in collaboration, cooperation, sponsorship and the development of joint initiatives with relevant organizations in the domains of gero-science, the economics of ageing and Longevity policy, politics and governance. The foundation has a strong history of cross-sector collaboration that includes projects on the development of actionable biomarkers of ageing and the application of Artificial Intelligence for ageing research, on interfacing with international policy organizations like the WHO on classifying ageing as a disease, and with financial institutions on economic reform to transform the problem of ageing population into the opportunity of Healthy Longevity.

III. Donations from Individual and Institutional Sponsors

In order to move forward with its expanded scope of activities in the realms of Longevity policy, politics, governance and synergetic industry development, the Biogerontology Research Foundation is actively seeking donations from key institutional and individual sponsors that are keen to see the United Kingdom manifest its latent strengths and prospects, and become the leading Longevity nation that it has the potential to be.
The Biogerontology Research Foundation is the UK’s leading non-profit foundation specifically focused on Longevity and on expediting the coming paradigm shift from disease treatment to personalized precision prevention. It was the main initial donor that provided financial and organisational support to Longevity International UK for the purpose of establishing the APPG for Longevity. It was also actively involved in the successful initiative of adding a new extension code for “ageing-related diseases” accepted in 2018 by the World Health Organization during the last revisions of its International Classification of Diseases framework.